Loading company…
France-based developer of READTHROUGH compounds for genetic diseases and cancers caused by nonsense mutations.
Urania Therapeutics develops READTHROUGH compounds intended to restore full-length protein synthesis in genetic diseases and cancers caused by nonsense mutations. Founded in 2015 and headquartered in France, the company raised EUR 789,500 in a Series A round led by NovAliX and Capital Grand Est, with EUR 789,500 raised in total by July 2021. Its valuation is listed at EUR 4.382 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in